Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation

Table 2 Comparison of patient-reported outcomes between the concordant and discordant groups in the prospective substudy

Patient-reported outcome	Concordant group (n = 20)	Discordant group^a (n = 46)	P value
Pain VAS	25.0 (11.0–42.5)	49.0 (28.0–70.0)	.002
SF-MPQ-2 pain score
Continuous	2.2 (1.8)	3.3 (2.0)	.03
Intermittent	1.8 (2.2)	1.8 (2.0)	.71
Neuropathic	1.2 (1.4)	2.0 (1.8)	.045
Affective	1.1 (1.4)	1.7 (2.0)	.06
Total	1.2 (0.4–2.7)	2.1 (1.2–2.9)	.09
Fibromyalgia Research Survey
WPI	4.5 (2.5–7.0)	7.0 (5.0–10.0)	.008
SS score	3.5 (2.0–5.5)	4.5 (3.0–6.0)	.05
Polysymptomatic distress	7.5 (5.5–12.5)	11.5 (9.0–16.0)	.007
BRAF score	5.0 (3.8–5.5)	5.3 (4.3–6.7)	.10
PROMIS
Fatigue	2.4 (1.4–3.4)	2.8 (2.0–3.8)	.22
Pain interference	1.7 (1.3–2.6)	2.2 (1.6–3.1)	.04
Sleep disturbance	2.0 (1.4–3.4)	2.8 (2.0–3.8)	.09
Ability to participate	3.9 (3.4–4.5)	3.5 (3.0–4.1)	.06
HAQ-II disability	0.4 (0.1–1.1)	1.0 (0.5–1.4)	.003
MAAS	4.6 (4.2–5.3)	5.1 (4.5–5.4)	.19
PHQ-9	2.5 (1.0–6.0)	4.0 (3.0–6.0)	.18
GAD-7	1.0 (0.0–1.5)	1.0 (0.0–3.0)	.12

Values are presented as median (interquartile range)
^a Discordant group contains only those patients with patient global assessment greater than physician global assessmen
BRAF Bristol Rheumatoid Arthritis Fatigue, GAD-7 Generalized Anxiety Disorder 7, HAQ-II Health Assessment Questionnaire II, MAAS Mindful Attention Awareness Scale, PHQ-9 Patient Health Questionnaire 9, PROMIS Patient-Reported Outcome Measurement Information System, SF-MPQ-2 Short-Form McGill Pain Questionnaire 2, SS Symptom Severity, VAS visual analog scale, WPI Widespread Pain Index

ISSN: 1478-6362